Abstract:Metal-based complexes have occupied a pioneering niche in the treatment of many chronic diseases, including various types of cancers. Despite the phenomenal success of cisplatin for the treatment of many solid malignancies, a limited number of metallo-drugs are in clinical use against cancer chemotherapy till date. While many other prominent platinum and non‑platinum- based metallo-drugs (e.g. NAMI-A, KP1019, carboplatin, oxaliplatin, titanocene dichloride, casiopeinas® etc) have entered clinical trials, many have failed at later stages of R&D due to deleterious toxic effects, intrinsic resistance and poor pharmacokinetic response and low therapeutic efficacy. Nonetheless, research in the area of medicinal inorganic chemistry has been increasing exponentially over the years, employing novel target based drug design strategies aimed at improving pharmacological outcomes and at the same time mitigating the side-effects of these drug entities. Over the last few decades, natural products became one of the key structural motifs in the anticancer drug development. Many eminent researchers in the area of medicinal chemistry are devoted to develop new 3d-transition metal-based anticancer drugs/repurpose the existing bioactive compounds derived from myriad pharmacophores such as coumarins, flavonoids, chromones, alkaloids etc. Metal complexes of natural alkaloids and their analogs such as luotonin A, jatrorrhizine, berberine, oxoaporphine, 8-oxychinoline etc. have gained prominence in the anticancer drug development process as the naturally occurring alkaloids can be anti-proliferative, induce apoptosis and exhibit inhibition of angiogenesis with better healing effect. While some of them are inhibitors of ERK signal-regulated kinases, others show activity based on cyclooxygenases-2 (COX-2) and telomerase inhibition. However, the targets of these alkaloid complexes are still unclear, though it is well-established that they demonstrate anticancer potency by interfering with multiple pathways of tumorigenesis and tumor progression both in vitro and in vivo. Over the last decade, many significant advances have been made towards the development of natural alkaloid-based metallo-drug therapeutics for intervention in cancer chemotherapy that have been summarized below and reviewed in this article.

Update of Metal-Based Drugs:Problems and Approaches for Solution

Construction of Arsenic-Metal Complexes Loaded Nanodrugs for Solid Tumor Therapy: A Mini Review.

Development of Metal-Based Drugs and Application in Clinical Treatment

New Strategies and Trends for the Design of Metal-Based Anticancer Drugs

Frontier of Development for Metallodrugs on the Basis of Metallomic Pharmacology and Medicinal Inorganic Chemistry

Research Progress of Metal Anticancer Drugs

Metallo-Drugs in Cancer Therapy: Past, Present and Future

Metal-based drugs

Medicinal inorganic chemistry: an updated review on the status of metallodrugs and prominent metallodrug candidates

Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

Challenges for Metals in Medicine: How Nanotechnology May Help To Shape the Future

Recent updates in nanoscale delivery systems of platinum(IV) antitumor prodrugs

A Contemporary Update

Stimuli-Responsive Therapeutic Metallodrugs

Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects

A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies

Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

Supramolecular Coordination Complexes As Diagnostic and Therapeutic Agents

The Pharmacological/toxicological Effects and Rational Drug Design of Vanadium Complexes

Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses.